SmallCapInsights.com Investment Newsletter Commences Editorial Coverage of MultiCell Technologies Following Recently Filed Patent on Cancer Treatment.

Editors Spotlight MCET's Strategy to Develop First-in-Class Drugs Based on Unique Immune-Modulation Technologies

SAN DIEGO -- SmallCapInsights.com, a leading investment newsletter committed to discovering tomorrow's smallcap breakthroughs, has announced the online release of a new installment of compensated coverage of MultiCell Technologies (the "Company") (OTCBB:MCET), an integrated biopharmaceutical company that uses proprietary immune system modulation technologies to discover and commercialize new therapeutics.

In an newsletter article released today, SmallCapInsights addresses MultiCell's most recent patent announcementCo"Methods for Tumor Control and Treatment by Loading an Antigen Presenting Cell," and provides investors with background on the Company and opinion on its progress and potential.

The articles states that "companies such as MultiCell Technologies (OTCBB:MCET) are on the cutting edge of bringing this type of biotech rocket science to the healthcare sector and, most importantly, to the benefit of millions of patients who suffer from debilitating maladies."

The article continues with a discussion of MultiCell's drug candidates, which are currently focused on treating afflictions such as Multiple Sclerosis (MS) type-1 diabetes and infectious disease such as influenza. With its recent patent filing, the Company has expanded its focus to the treatment of malignant tumors resulting from various forms of cancer. The Company has more than 40 issued, pending and applied-for patents covering its novel drug development technology.

Within the most recent Company press release, Dr. Stephen Chang, President and Chief Executive Officer of MultiCell, stated: "We believe that this patent filing further validates our scientific and business model to develop drug candidates that work with the body's own immune system to deliver an entirely new generation of disease-specific immunotherapeutics."

The article in SmallCapInsights continues: "The Company's first-in-class therapeutic pipeline currently includes MCT-125, a treatment for chronic fatigue in MS patients, MCT-175, for the treatment of relapsing-remitting MS, MCT-275 for the treatment of type-1 diabetes, and MCT-465, a TLR agonist adjuvant therapy targeting virus infection. MCT-465 has further demonstrated effectiveness in reducing HIV and HCV levels in animal models."

The potential for MultiCell's growth appears compelling, according to SmallCapInsights. The article explains, "These critical, yet underserved afflictions/markets have massive profit potential for utilizing novel therapeutics."

SmallCapInsights will provide ongoing coverage of this unique company. Investors can access the article at http://www.smallcapinsights.com.

About MultiCell Technologies, Inc.

MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology. MultiCell's drug development program is focused on modulation of the immune system. The Company's lead drug candidates include drugs to treat MS-related chronic fatigue, relapsing-remitting multiple sclerosis, type-1 diabetes and infectious disease. The Company also holds unique cell-based technology for use in drug discovery screening applications and the production of therapeutic proteins, and is a leading producer of immortalized human hepatocyte cell lines needed by the biotechnology and pharmaceutical industries to develop new drugs and therapeutics. For more information about MultiCell Technologies, please visit http://www.MultiCelltech.com. For investor information about MultiCell, please visit http://www.trilogy-capital.com/tcp/multicell. For current stock price quotes and news, visit http://www.trilogy-capital.com/tcp/multicell/quote.html. To view the Company's Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/multicell/factsheet.html. To listen to an archived investor conference call, visit http://www.trilogy-capital.com/tcp/multicell/conference/html.

About SmallCapInsights.com

The editors and publishers of SmallCapInsights.com have decades of direct experience both in the markets and in the newsletter genre as well as being avid students of the sector. The Companies we illuminate and represent are those we feel have the best chance of enhancing portfolio returns as we take them from initial profile to ongoing in-depth coverage. We aren't married to any space within the smallcap sector, just to those ideas and strategies that will make our opinions and observations a relevant starting point to your complete and ongoing due diligence. The good, the bad and the bizarre -and hopefully profitable--will populate our pieces. Our readers will first and foremost be our priority. Every article will include a detailed disclaimer. We are not analysts, but rather view our picks as an investor might: questioning, commenting and delivering our best opinions, be they pro or con. As well, in each piece we will highlight a technical opinion, which, though it can never be definitive, will serve to give readers a quick snapshot of our current T/A thoughts. For more information, visit http://www.smallcapinsights.com.

Compensation Disclosures

Editorial is provided by SmallcapInsights.com ("Smallcap") to provide readers with information on publicly traded companies which have retained Smallcap to provide editorial commentary. Smallcap receives compensation for those services from the company, which consists of cash and/or securities of the company. Factual information is obtained from public filings and other sources deemed to be reliable; however, Smallcap takes no responsibility for verifying the accuracy of such information and makes no representation that such information is accurate or complete. Further, Smallcap and its employees and affiliates may own, or may purchase and sell, securities of the companies profiled. Smallcap undertakes no obligation to inform readers about the ownership or trading activities of it or its employees or affiliates in the securities of the profiled companies. As of September 26, 2006, SmallcapInsights.com receives from MultiCell Technologies an aggregate of US$21,500 for six months of editorial coverage.

Forward-Looking Statements

Certain of the statements in this website may be considered forwarded looking statements. Smallcap makes no representation and provides no assurance or guaranty that such forward looking statements will be prove to be accurate. Statements of opinion and belief are those of the authors and/or editors of this website, and are based solely upon the information possessed by such authors and/or editors; no inference should be drawn that such authors or editors have any special or greater knowledge about the companies profiled or any particular expertise in the industries or markets in which the profiled companies compete. The reader should verify all claims and complete his own due diligence before investing in any securities of profiled companies. Neither Smallcap nor anyone involved in the publication of this editorial is a registered investment adviser or broker/dealer. Smallcap makes no recommendation that the purchase of securities of companies profiled in this editorial is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. An investor in such securities should be prepared and able to bear a loss of his or her entire investment. Nothing in this editorial should be construed as an offer or solicitation to buy or sell any securities of any profiled company.